CADTH Canadian Drug Expert Committee recommendation: Travoprost 0.003% (Izba -- Novartis Pharmaceuticals Canada inc. on behalf of Alcon Canada Inc.) indication : for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
The CADTH Canadian Drug Expert Committee (CDEC) recommends that travoprost 0.003% preserved with polyquaternium-1 (PQ) be reimbursed for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT), if the following condition is met: Th...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2017, October 2017
|
| Edition: | Version: 1.0 |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that travoprost 0.003% preserved with polyquaternium-1 (PQ) be reimbursed for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT), if the following condition is met: The drug plan cost of treatment with travoprost 0.003% PQ should not exceed the drug plan cost of treatment with the least costly alternative prostaglandin analogue (PGA) |
|---|---|
| Item Description: | "Final." |
| Physical Description: | 1 PDF file (5 pages) |